Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-specific T cell therapy for refractory CMV after SCT
NCT03067155Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Oct 2016
- Primary completion
- Dec 2021
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CMV-specific T cells (University Hospital, Ghent) in cytomegalovirus infection (CMV), sponsored by Ghent University Hospital. Started Oct 2016; status: completed.
02
Drugs
CMV-specific T cells (University Hospital, Ghent)
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03067155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03067155.